Clinical Trial Update: ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

The ADAPT trial in early breast cancer (Phase 2/3) has completed its program, providing a final update on this dynamic marker-adjusted personalized therapy appr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED